Use of non-steroidal anti-inflammatory drugs and risk of breast cancer : The Spanish Multi-Case-control (MCC) study
Dierssen-Sotos, Trinidad (Universidad de Cantabria)
Gomez-Acebo, Ines (Universidad de Cantabria)
de Pedro, María (Hospital Universitario HM Nuevo Belén (Madrid))
Pérez-Gómez, Beatriz (Instituto Investigación Sanitaria Puerta de Hierro (Madrid))
Servitja, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques)
Morros, Rosa (Institut d'Investigació Biomèdica de Bellvitge)
Amiano, Pilar (Biodonostia Osasun Ikerketako Institutura (País Basc))
Fernández-Villa, Tania (Universidad de León)
Barricarte, Aurelio (Instituto de Investigación Sanitaria de Navarra)
Tardón, Adonina (Universidad de Oviedo)
Diaz-Santos, Marian (Centro de Investigación en Salud y Medio Ambiente (Huelva, Andalusia))
Peiro-Perez, Rosana (Area de Cáncer y Salud Pública, Fundación (València))
Marcos-Gragera, Rafael (Institut Català d'Oncologia)
Lope, Virginia (Instituto Investigación Sanitaria Puerta de Hierro (Madrid))
Gracia-Lavedan, Esther (Universitat Pompeu Fabra)
Alonso, M. Henar (Institut d'Investigació Biomèdica de Bellvitge)
Michelena-Echeveste, Maria Jesus (Instituto Oncologico (Sant Sebastià, País Basc))
Garcia-Palomo, Andrés (Complejo Asistencial Universitario de León)
Guevara, Marcela (Instituto de Investigación Sanitaria de Navarra)
Castaño-Vinyals, Gemma (Institut Hospital del Mar d'Investigacions Mèdiques)
Aragonés, Nuria (Instituto Investigación Sanitaria Puerta de Hierro (Madrid))
Kogevinas, M (Universitat Pompeu Fabra)
Pollán, Marina (Instituto Investigación Sanitaria Puerta de Hierro (Madrid))
Llorca, Javier (Universidad de Cantabria)
Universitat Autònoma de Barcelona

Data:	2016
Resum:	The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i. e. : ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i. e. : menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0. 76; 95 % Confidence Interval [CI]: 0. 64-0. 89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i. e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. The online version of this article (doi:10. 1186/s12885-016-2692-4) contains supplementary material, which is available to authorized users.
Ajuts:	Instituto de Salud Carlos III PI08/1770 Instituto de Salud Carlos III PI08/0533 Instituto de Salud Carlos III PI08/1359 Instituto de Salud Carlos III PI09/00773 Instituto de Salud Carlos III PI09/01286 Instituto de Salud Carlos III PI09/01903 Instituto de Salud Carlos III PI09/02078 Instituto de Salud Carlos III PI09/01662 Instituto de Salud Carlos III PI11/01403 Instituto de Salud Carlos III PI11/01889 Instituto de Salud Carlos III PI11/00226 Instituto de Salud Carlos III PI11/01810 Instituto de Salud Carlos III PI11/02213 Instituto de Salud Carlos III PI12/00488 Instituto de Salud Carlos III PI12/00265 Instituto de Salud Carlos III PI12/01270 Instituto de Salud Carlos III PI12/00715 Instituto de Salud Carlos III PI12/00150 Instituto de Salud Carlos III PI14/01219 Ministerio de Economía y Competitividad RD12/0036/0036 Generalitat de Catalunya 2009SGR1489 European Commission 036224
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Breast cancer ; Non-steroidal anti-inflammatory drug ; Hormone receptor positive breast cancer ; HER2 positive breast cancer ; Triple negative breast cancer
Publicat a:	BMC Cancer, Vol. 16 (august 2016) , ISSN 1471-2407

DOI: 10.1186/s12885-016-2692-4
PMID: 27542890

11 p, 462.0 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats